A clinical trial (NCT04101851) has just commenced evaluating whether it is oncologically safe to omit SLNB in triple-negative and HER2-positive breast cancer patients with radiologic and pathological complete response in the breast after NST [38]. This evidence concerns the gene ERBB2 and breast carcinoma.